Beattie EC, Carroll RC, Yu X, Morishita W, Yasuda H, von Zastrow M et al (2000)
This work was partially supported by the National Natural Science Foundation of China (82273961, 82073904, 81872915 to M.-W.W., 82273985, 82121005, 81973373 to D.Y., 32200576, 32071203 to L.-H.Z., 82121005 to H.E.X
Research is needed to establish exposure biomarkers, determine tissue dosing and dosimetry (to facilitate extrapolation of preclinical studies), assess lung function, and identify early injury indicators in human users
& Coyte, P
Abbreviations ESKD: End-stage kidney disease GLP-1 RA: Glucagon-like peptide-1 receptor agonist HF: Heart failure ICER: Incremental cost-effectiveness ratio MI: Myocardial infarction NDSS: National Diabetes Services Scheme QALY: Quality-adjusted life year SGLT2i: Sodiumglucose co-transporter 2 inhibitor References McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
Use the scroll bar at the bottom of the chart to see more data